Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schiff Nutrition Q1 Sales Increases
Schiff Nutrition International has reported a net sales of $48.6m for the three months ended August 31, 2009, an increase when compared to $47.8m for the same period
Schiff Nutrition International has reported a net sales of $48.6m for the three months ended August 31, 2009, an increase when compared to $47.8m for the same period
Pharmacyclics has reported a GAAP net loss of $5.4m, or $0.20 per share for the fourth quarter of fiscal 2009, compared to a net loss of $4.6m, or
The Linde Group has launched its research and development (R&D) centre in Shanghai, taking the lead in the development of new high technology industrial gas applications and solutions
Tianyin Pharmaceutical (Tianyin) has received the Good Manufacturing Practices Certificate for pharmaceutical products (GMP Certificate) from the State Food and Drug Administration (SFDA) in China. Reportedly, based on
Abbott is in the process of launching, more than 40 sustainable packaging initiatives across its nutrition, pharmaceutical and medical products businesses to meet its goal of a 5%
Smith & Nephew’s Advanced Wound Management division, announced that it is launching two extensions to the ALLEVYN Ag range of dressings; ALLEVYN Ag Gentle Border and ALLEVYN Ag
NuPhysicia, the parent group of InPlace Medical Solutions, has announced the formation of NUPHYSICIA SERVICOS MEDICOS OFFSHORE LTDA, its Brazil-based subsidiary providing physician services to its Brazil-based customers.
Teva Women’s Health has announced that its Plan B One-Step (levonorgestrel) tablet, 1.5mg emergency contraceptive is now available at licensed US retail pharmacies. Approved by the FDA on
Details of the emerging technology were revealed during a lecture at the Health Protection Agency’s annual conference at the University of Warwick. “If there was a major radiological
Sosei Group (Sosei) has announced that Novartis have presented the results of their two phase II studies evaluating the efficacy, safety and tolerability of QVA149 at the annual